Science & Medicine

MET-Amplified Lung Cancer: A New Target for XALKORI?

GRACEcast by Howard (Jack) West, MD

Jul 3, 201407:18Science & Medicine

Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positive patients.

About This Episode

MET-Amplified Lung Cancer: A New Target for XALKORI? is an episode from GRACEcast by Howard (Jack) West, MD. Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positiv...

Podcast

This episode belongs to GRACEcast.

Listen Online

Use the player on this page to stream the episode online.

Episode Details

Published Jul 3, 2014, 07:18 long, audio available.

MET-Amplified Lung Cancer: A New Target for XALKORI?

About This Episode

Related Episodes